

Mortality Caused by Late-onset Sepsis in Very Low Birth Weight Infants: Risk Analysis and the Performance of Diagnostic Tools

Hakan Ongun¹ and Meltem Demir²

¹Division of Neonatology, Department of Pediatrics, Faculty of Medicine, İstinye University Antalya Medical Park Hospital, Antalya, Turkey

²Department of Medical Biochemistry, Faculty of Medicine, İstinye University, Antalya, Turkey

ABSTRACT

Objective: To assess the risk on late-onset sepsis attributed mortality in very low birth weight (VLBW) infants.

Study Design: Observational study.

Place and Duration of Study: Level-III Neonatal Intensive Care Unit, İstinye University, Antalya Medical Park Hospital, Turkey, between January 2014 and December 2018.

Methodology: Perinatal characteristics and clinical features of 198 septic preterm neonates were evaluated to predict sepsis-attributed mortality. ROC analysis was employed to drive optimal-cutoffs for laboratory parameters and logistic regression to calculate mortality risk factors using SPSS version-22 and MedCalc software.

Results: Mean gestational age was 28.91 ±2.67 weeks. Umbilical catheterisation was the principal risk factor for culture-positive sepsis (OR 2.860, 95%CI: 1.232-6.639). Outborn infants were more likely to deliver surfactant and longer intubation (p=0.013, and p=0.005, respectively), manifested frequent BPD (p=0.014), and at greater risk of proven sepsis and mortality (OR: 1.796, 95%CI: 1.011-3.191; OR: 1.950, 95%CI: 1.002-3.794). Low Apgar scores necrotising enterocolitis (NEC) and prolonged intubation were independent risk factors for mortality (OR: 13.840, 95%CI: 6.384-30.005; OR: 5.410, 95%CI: 2.113-13.849; OR: 10.037, 95%CI: 4.700-21.434). An increase in high-sensitivity C-reactive protein (hsCRP)-ratio >6.08-fold afforded good sensitivity and specificity (AUC: 0.914; sensitivity: 89.36%, specificity: 86.09%). Logistic regression of various combinations has shown a >6.08-fold change in hsCRP-ratio over 24-hours and platelet counts <88x10⁹/L optimally predicted mortality (OR: 27.983, 95%CI: 9.704-80.697).

Conclusion: Low Apgar scores, NEC and prolonged intubation are independent risk factors for mortality of VLBW infants. Birth in level III-IV NICUs featuring special neonatal care, avoidance of prolonged intubation, and timely prediction of fatal sepsis using hsCRP ratio and platelets could prevent sepsis-related mortality.

Key Words: Sepsis, Very low birth weight, Infant formality, Apgar score.

How to cite this article: Ongun H, Demir M. Mortality Caused by Late-onset Sepsis in Very Low Birth Weight Infants: Risk Analysis and the Performance of Diagnostic Tools. *J Coll Physicians Surg Pak* 2020; **30(06)**:611-616 <https://doi.org/10.29271/jcpsp.2020.06.611>.

INTRODUCTION

Late-onset sepsis (LOS) is one of the most devastating problems encountered in neonatal intensive care units (NICUs).¹ The incidence ranges from 5 to 29.4% in very low birth weight (VLBW) infants, 10-fold that of their term-born counterparts.^{2,3} Although the incidence of LOS has declined modestly, LOS remains a life-threatening problem in both high- and low-income countries.⁴

VLBW infants are at increased risk of invasive infections because their neutrophil functions are poor and their maternally-acquired immunoglobulin levels low.^{3,6} Early recognition of a septic infant and timely antibiotic therapy are key factors to determine mortality.⁷ Unfortunately, the subtle and indistinct clinical symptoms cause diagnostic delays. Although several predictive models and aids to diagnosis (e.g. cytokine levels) have been developed, the reference values vary by gestational age (GA) and postnatal age, rendering interpretation challenging.^{3,8} The associated financial costs limit the utility of specific markers in low- to middle-income countries.³ It is essential to identify a deteriorating septic infant using routine laboratory parameters. The objective of this observational cohort study of VLBW infants, was to determine the risk for LOS mortality and assess the predictive utility of sepsis work-up tools commonly used in daily practice.

Correspondence to: Hakan Ongun, Faculty of Medicine, İstinye University, Antalya Medical Park Hospital, Tekeli-oglu Caddesi No. 7, Muratpasa, Antalya, Turkey
E-mail: hongun88@hotmail.com

Received: April 15, 2020; Revised: June 13, 2020;
Accepted: June 26, 2020

DOI: <https://doi.org/10.29271/jcpsp.2020.06.611>

Table I: Demographics and risk factors for mortality.

Demographics	Non-survivors (n=47)	Survivors (n=151)	Odds ratio (95% CI)	p-value
Gestational age, (weeks) (mean \pm SD)	27.38 \pm 2.79	29.39 \pm 2.46	0.745 (0.651 - 0.853)	<0.001
Birth weight, (grams) (mean \pm SD)	1020.26 \pm 410.06	1308.59 \pm 428.62	0.998 (0.997 - 0.999)	<0.001
Male gender, (%)	30 (63.8%)	75 (49.7%)	1.788 (0.910 - 3.513)	0.092
Maternal age, (years) (mean \pm SD)	28.53 \pm 5.90	29.48 \pm 6.52	0.976 (0.927 - 1.029)	0.371
Maternal condition, (%)	10 (21.3%)	47 (31.1%)	0.598 (0.274 - 1.303)	0.196
Preeclampsia, (%)	5 (10.6%)	33 (21.9%)	0.426 (0.156 - 1.162)	0.096
Gestational diabetes mellitus, (%)	4 (8.5%)	7 (4.6%)	1.914 (0.535 - 6.847)	0.318
Twins, (%)	10 (21.3%)	52 (34.4%)	0.515 (0.237 - 1.117)	0.093
Outborn infant, (%)	28 (59.6%)	65 (43%)	1.950 (1.002 - 3.794)	0.049
Intrauterine transport, (%)	10 (21.3%)	10 (6.6%)	3.811 (1.476 - 9.837)	0.006
CS delivery, (%)	38 (80.9%)	134 (88.7%)	1.867 (0.771 - 4.522)	0.162
PROM, (%)	2 (4.3%)	6 (4.0%)	1.074 (0.209 - 5.509)	0.932
Risk factors				
5. Minutes Apgar score <7, (%)	34 (72.3%)	24 (15.9%)	13.840 (6.384 - 30.005)	<0.001
Surfactant administration, (%)	46 (97.9%)	90 (59.6%)	31.178 (4.187-232.142)	0.001
Length of intubation >5 days a, (%)	35 (74.5%)	34 (22.5%)	10.037 (4.700 - 21.434)	<0.001
CPAP therapy	1 (2.1%)	127 (84.1%)	0.004 (0.001 - 0.031)	<0.001
Bronchopulmonary dysplasia, (%)	0 (0%)	19 (12.6%)	-	NA
VP shunt, (%)	1 (2.1%)	5 (3.3%)	0.635 (0.072 - 5.573)	0.682
PDA, (%)	16 (34.0%)	52 (34.4%)	0.983 (0.493 - 1.960)	0.960
NEC, (%)	12 (25.5%)	9 (6%)	5.410 (2.113 - 13.849)	<0.001
Umbilical catheter, (%)	47 (100%)	114 (75.5%)	-	NA
Peripherally-inserted central venous catheter, (%)	24 (51.1%)	24 (15.9%)	5.522 (2.690 - 11.336)	<0.001
Antacid medication, (%)	18 (38.3%)	0 (0%)	-	NA
Urine catheter, (%)	0 (0%)	3 (2%)	-	NA
Culture positivity, (%)	20 (42.6%)	59 (39.1%)	1.155 (0.594 - 2.244)	0.671
Coagulase (-) staphylococcus	8 (17.0%)	19 (12.6%)	1.425 (0.579 - 3.505)	0.440
Enterococcus*	1 (2.1%)	17 (11.3%)	0.171 (0.022 - 1.324)	0.091
Gram (-) bacteria **	8 (17.0%)	23 (15.2%)	1.142 (0.473 - 2.754)	0.768
Fungi	3 (6.4%)	0 (0%)	-	NA

*Logistic regression was performed to calculate odds ratios for mortality.⁹ Length of endotracheal intubation >5 days (AUC: 0.716, 95% CI: 0.634 - 0.789, p <0.001; obtained by ROC analysis). * Enterococcus includes both Vancomycin-resistant and Vancomycin-sensitive strains; ** Gram (-) bacteria includes Acinetobacter baumannii, Klebsiella pneumonia and Serratia marcescens. NA: not applicable.*

METHODOLOGY

This observational study was approved by the Institutional Review Board (approval No. 2019/3, dated April 23, 2019).

The medical records of NICU admissions with ICD-codes of 'neonatal sepsis between January 2014 and December 2018 were retrospectively extracted from the hospital patient database. All preterm infants of GA<32 weeks and birth weight <1,500 g, with at least one episode of LOS (sepsis after 3 days of life) were included. Infants with early-onset sepsis, intraventricular haemorrhage and/or who underwent any surgical inter-

vention prior to sepsis suspicion were excluded because the laboratory data might be affected by inflammation.

Pre- and ante-natal data included; birthplace (outborn: born elsewhere and then transferred to the study unit); clinical sepsis signs (apnea, increased oxygen-dependence, feeding intolerance, skin mottling, tachycardia, impaired peripheral perfusion and mental status, lethargy, seizures, temperature instability, and unexplained acidosis);⁹ and potential sepsis risk factors were extracted from patients' records. If two blood cultures were positive for coagulase-negative (CoNS), it was considered that CoNS caused the sepsis *staphylococci*.¹⁰

Table II: The performance of diagnostic tools to determine mortality.

	Cut-off value	AUC (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	LH+ (95% CI)	PPV (95% CI)	NPV (95% CI)	P
Day 1								
hsCRP _{day0} (mg/dL)	1.08	0.621 (0.540-0.703)	72.34 (57.4-84.4)	58.28 (50.0-66.2)	1.73 (1.3-2.2)	35.1 (25.6-45.4)	87.1 (79.0-93.0)	0.0035
Hematocrit (%)	46.8	0.509 (0.422-0.597)	72.34 (57.4-84.4)	39.7 (31.9-48.0)	1.20 (1.0-1.5)	27.2 (19.6-35.9)	82.2 (71.5-90.2)	0.838
WBC (x10 ⁹ /L)	22.3	0.611 (0.504-0.718)	42.55 (28.3-57.8)	87.42 (81.0-92.3)	3.38 (2.0-5.8)	51.3 (34.8-67.6)	83.0 (76.3-88.5)	0.042
Neutrophil count(x10 ⁹ /L)	1.6	0.528 (0.431-0.625)	25.53 (13.9-40.3)	83.44 (76.5-89.0)	1.54 (0.8-2.8)	32.4 (18.0-49.8)	78.3 (71.1-84.4)	0.570
NLR	3.66	0.508 (0.413-0.604)	10.64 (3.5-23.1)	96.69 (92.4-98.9)	3.21 (1.0-10.6)	50.0 (18.7-81.3)	77.7 (71.0-83.4)	0.865
PLR	34.57	0.502 (0.408-0.596)	25.53 (13.9-40.3)	63.58 (55.4-71.2)	0.70 (0.4-1.2)	17.9 (9.6-29.2)	73.3 (64.8-80.6)	0.966
Platelets count (x10 ⁹ /L)	88	0.534 (0.437-0.631)	19.15 (9.1-33.3)	90.73 (84.9-94.8)	2.07 (1.0-4.5)	39.1 (19.7-61.5)	78.3 (71.5-84.2)	0.496
MPV	9.6	0.532 (0.435- 0.629)	38.30 (24.5-53.6)	72.19 (64.3-79.2)	1.38 (0.9-2.1)	30.0 (18.8-43.2)	79.0 (71.2-85.5)	0.517
Day 1								
hsCRP _{day1} (mg/dL)	7.17	0.868 (0.815-0.921)	93.62 (82.5-98.7)	66.89 (58.8-74.3)	2.83 (2.2-3.6)	46.8 (36.4-57.4)	97.1 (91.8-99.4)	<0.001
Change in hsCRP ratio	6.08	0.914 (0.857-0.971)	89.36 (76.9-96.5)	86.09 (79.5-91.2)	6.43 (4.3-9.7)	66.7 (53.7-78.0)	96.3 (91.6-98.8)	<0.001
Hematocrit (%)	38.7	0.507 (0.410-0.604)	34.04 (20.9-49.3)	72.19 (64.3-79.2)	1.22 (0.8-2.0)	27.6 (16.7-40.9)	77.9 (70.1-84.4)	0.889
WBC (x10 ⁹ /L)	18.41	0.510 (0.413-0.607)	44.68 (30.2-59.9)	64.90 (56.7-72.5)	1.27 (0.9-1.9)	28.4 (18.5-40.1)	79.0 (70.8-85.8)	0.837
Neutrophil count(x10 ⁹ /L)	8.1	0.503 (0.409-0.598)	65.96 (50.7-79.1)	28.48 (21.4-36.4)	0.92 (0.7-1.2)	22.3 (15.7-30.1)	72.9 (59.7-83.6)	0.943
NLR	0.80	0.502 (0.407-0.598)	38.30 (24.5-53.6)	55.63 (47.3-63.7)	0.86 (0.6-1.3)	21.2 (13.1-31.4)	74.3 (65.3-82.1)	0.960
PLR	34.23	0.550 (0.449-0.651)	51.06 (36.1-65.9)	66.89 (58.8-74.3)	1.54 (1.1-2.2)	32.4 (22.0-44.3)	81.5 (73.5-87.9)	0.331
Platelets count (x10 ⁹ /L)	285	0.577 (0.483-0.670)	72.34 (57.4-84.4)	46.36 (38.2-54.6)	1.35 (1.1-1.7)	29.6 (21.4-38.8)	84.3 (74.7-91.4)	0.108
MPV	10.2	0.558 (0.463-0.654)	51.06 (36.1-65.9)	63.58 (55.4-71.2)	1.40 (1.0-2.0)	30.4 (20.5-41.8)	80.7 (72.4-87.3)	0.231

*Statistics were obtained by ROC analysis; AUC: area under the curve; LH+: likelihood ratio; PPV: positive predictive value; NPV: negative predictive value.

Table III: The combination of diagnostic tools for sepsis-attributed mortality.

	Exp (B)	95% C.I. for EXP (B)		p
		Lower	Upper	
CRP _{day0}	1.022	0.815	1.281	0.853
CRP _{day1}	1.173	1.119	1.229	<0.001
White blood cell count (WBC) _{day0}	1.058	1.026	1.090	<0.001
White blood cell count (WBC) _{day1}	1.004	0.973	1.036	0.804
Platelets count _{day0}	0.993	0.990	0.997	<0.001
Platelets count _{day1}	0.998	0.996	1.000	0.084
[Change in hsCrp ratio >6.08] + [Platelets _{day0} <88.000 mm ³]	27.983	9.704	80.697	<0.001
[Change in hsCrp ratio >6.08] + [WB _{day0} >22300 mm ³]	18.124	6.230	52.730	<0.001
[Platelets _{day0} <88.000mm ³] + [WBC _{day0} >22300 mm ³]	16.914	4.529	63.172	<0.001

Statistics obtained by logistic regression.

Infants were grouped by blood culture data (proven sepsis: blood culture positivity with clinical deterioration; clinical sepsis: clinical deterioration in the absence of culture positivity)¹¹ and survival (survivors and non-survivors). Sepsis work-up included both a complete blood cell count (CBC) and high-sensitivity C-reactive protein CRP (hsCRP) measurements on the day of clinical sepsis suspicion (day 0) and 24 hours thereafter (day 1). Hematocrit, white blood cell count (WBC), neutrophil and lymphocyte counts and percentage, the neutrophil/lymphocyte ratio (NLR), the platelet count, the mean

platelet volume (MPV), the platelet/lymphocyte ratio (PLR) and the hsCRP level were analysed. A WBC>20x10⁹/L evidenced leukocytosis and a WBC<4x10⁹/L leukopenia;¹² platelets count <100x10⁹/L indicated thrombocytopenia.¹³ Changes in hsCRP ratio were recorded between two serial measurements (calculated by the change of CRP level to the level at day 0).¹⁴

$$(\text{Changes in hsCRP ratio}) = \frac{(\text{hsCRP}_{\text{day1}} - \text{hsCRP}_{\text{day0}})}{\text{hsCRP}_{\text{day0}}}$$

CBCs were obtained using a Sysmex XN-1000 analyser (Symex, Japan). hsCRP measurements were automated using the immunoturbidimetric method of the modular analyser (Roche Diagnostics, Milano, Italy) (detection limit 0.03 mg/L).

SPSS version 22 software (IBM Corp., Armonk, NY, USA) was employed for statistical analyses. The Chi-squared and Fisher exact tests were used to compare categorical variables; continuous quantitative variables were compared with the aid of the Mann-Whitney U-test (non-normally distributed parameters) or the Student t-test (normally distributed parameters). Results were given as percentages (%), means \pm standard deviations, or medians with interquartile ranges (IQRs). Receiver operator characteristic (ROC) curves were drawn using MedCalc software (free trial version) and employed to derive optimal cutoffs, sensitivities, specificities, positive predictive values (PPVs), and negative predictive values (NPVs) of parameters associated with mortality. Logistic regression was employed to calculate mortality risk factors. Estimates were expressed as odds ratios (OR) with 95% confidence intervals (CI). A p-value <0.05 was considered to indicate statistical significance.

RESULTS

Two hundred and five preterm neonates of 914 NICU admissions were evaluated. Absent clinical or laboratory data has declined the study population to 198 VLBW infants. Males predominated (53%). The mean GA was 28.91 ± 2.67 weeks and the mean birth weight $1,240.15 \pm 440.76$ g. The median NICU stay was 52 days (IQR: 24-82.25 days). Forty-seven (23.7%) infants died of sepsis.

The proven sepsis rate was 39.9%. Patient demographics (including birth weight and GA) were similar between septic and non-septic infants, but the place of birth and maternal pre-eclampsia status differed ($p = 0.046$, and $p = 0.026$, respectively). Umbilical catheterisation was the principal sepsis risk factor for blood culture positivity (OR 2.860, 95% CI: 1.232-6.639). Infants with proven sepsis exhibited lower day 0 hematocrit and platelet counts, and major changes in hsCRP ratio made within 24 h ($p = 0.017$, $p = 0.001$, and $p = 0.022$, respectively).

Outborn infants constituted 47% of the study population. Although their birth weights and GA were similar to those of inborn infants ($p = 0.399$, and $p = 0.312$), outborns were at higher risk of respiratory morbidities requiring frequent surfactant delivery and longer endotracheal intubation and bronchopulmonary dysplasia (BPD), than inborns ($p = 0.013$, $p = 0.005$, and $p = 0.014$, respectively). Umbilical catheterisation was more often required ($p = 0.020$) and proven sepsis (predominantly Gram-negative bacteria) was more common ($p = 0.045$, and $p = 0.033$). Outborns were at greater risk of proven sepsis and mortality (OR: 1.796, 95% CI: 1.011-3.191, $p = 0.046$; OR: 1.950, 95% CI: 1.002-3.794, $p = 0.049$).

Table I lists mortality by patient demographics and the mortality risks revealed by logistic regression. Non-survivors had lower 5-min Apgar scores ($p < 0.001$) and required frequent invasive procedures (endotracheal surfactant administration, intubation, and venous catheterisation). Birth-place, the Apgar score, endotracheal intubation, necrotising enterocolitis (NEC), surfactant administration and peripheral central venous catheterisation status were evaluated through multivariate regression model. Low 5-min Apgar score was the most significant independent risk factor for sepsis mortality (OR: 13.840, 95% CI: 6.384-30.005), followed by NEC and intubation of more than 5 days (OR: 5.410, 95% CI: 2.113-13.849, $p < 0.001$ and OR: 10.037, 95% CI: 4.700-21.434, $p < 0.001$). The CBCs and hsCRP levels on days 0 and 1 were subjected to ROC analysis (Table II). Non survivors exhibited abnormal laboratory values (elevations in both parameters) on day 0 ($p = 0.042$, and $p = 0.0035$, respectively). The change in hsCRP ratio exhibited the highest area under the curve (AUC), sensitivity and specificity: a rise >6.08-fold predicted mortality with a sensitivity of 89.36% and a specificity of 86.09% (AUC: 0.914, PPV: 66.7%, NPV: 96.3%). An initial WBC $> 22.3 \times 10^9/L$ (AUC: 0.611, 95% CI: 0.504-0.718) was also associated with mortality. Logistic regression analysis of various combinations of laboratory data showed that the change in hsCRP ratio and initial thrombocytopenia (platelets count $< 88 \times 10^9/L$) optimally predicted mortality (OR: 27.983, 95% CI: 9.704-80.697) (Table III).

DISCUSSION

The 5-min Apgar score, NEC and prolonged endotracheal intubation were independent risk factors for mortality; outborn status affected respiratory outcomes and mortality; the change in hsCRP ratio (calculated from serial hsCRP measurements) sensitively and specifically indicated disease severity; and single laboratory parameters were poorly positively predictive but the combination of the initial platelet count and the change in hsCRP level powerfully predicted septic mortality.

Preterm delivery imposes physical challenges on the newborn. The associated oxidative stress, abnormal gut microbial colonisation and pathogen acquisition impose major risks for sepsis and NEC.^{3,15,16} Low Apgar scores at birth are also associated with an increased risk of bacterial infection.^{6,17} The reduced immunomodulation and impaired defense mechanisms caused by invasive procedures bring along additional risks in preterm infants.^{1,5,18} Low 5-min Apgar score, NEC and prolonged intubation (over 5 days) were three major risk factors for septic mortality, regardless of GA or birth weight. Moreover, non-survivors required frequent antacids (38%) and umbilical venous catheterisation. Central line-associated bloodstream infections and catheter dwell times over 15 days are known as the most common causes of healthcare-associated infections.¹⁹ Emphasising the previous statements, prolonged intubation and vascular

catheterisation should be avoided, and early enteral nutrition progressing to fully enteral feeding prioritised, to reduce the risk of infection during care of VLBW infants.

Birthplace was associated with LOS. Outborns were at increased risk of proven sepsis and mortality (OR: 1.796, 95%: 1.011-3.191 and OR: 1.950, 95% CI: 1.002-3.794). Although the birth weight and GA were similar to those of inborns, outborns were more likely to develop respiratory morbidities (requiring frequent surfactant delivery and longer intubation), BPD and Gram-negative sepsis. Earlier reports described poorer outcomes in terms of intubation requirements, ventilator-induced pneumonia, lung injury and BPD of VLBW neonates not born in level III or IV NICUs; the LOS and mortality rates attained 62%.²⁰ Even when the mortality rate (23.7%) was within the previously reported range of 16 to 25%,²⁷ birth in level III and IV NICUs delivering special neonatal care might reduce sepsis-related mortality in this population.

The utility of commonly available laboratory data was evaluated, when diagnostic biomarkers may not be assayed in the setting of limited resources. The CBC and CRP level are used by most clinicians to evaluate sepsis.⁷ Unfortunately, their predictive strengths are limited.^{4,6} The CBC alone lacks sensitivity (55 to 59%) in VLBW infants.^{2,7} Furthermore, the normal CRP range in VLBW infants is unknown given their poor response to inflammatory stimuli.²¹ The level of change in hsCRP ratio was used to identify infants who did not survive sepsis. Non-survivors evidenced significant abnormalities at the very early stage of clinical suspicion, including elevated hsCRP levels and WBCs, compared to survivors. ROC findings confirmed published data; serial hsCRP measurements and calculating the level of difference in the CRP ratio are the best predictors of sepsis mortality. CRP has a half-life of about 19 h and peaks 24-48 h after synthesis commences; serial measurements guide therapy.^{7,21} However, the meaningful significance of CRP variations between two-time points remains unclear.² Beltempo *et al.* found that a difference between two serial CRP measurements of less than 10 mg/L afforded an NPV of 93-97%.² Different thresholds from 1.5 to 20 mg/L were associated with wide ranges of sensitivity (48-78%) and specificity (71-88%).^{18,21} The change in hsCRP ratio exhibited the highest AUC of the present study; an increase >6.08-fold afforded good sensitivity and specificity (AUC: 0.914; sensitivity: 89.36, specificity: 86.09, PPV: 66.7%, NPV: 96.3%). The difference in the ratio of two serial measurements better predicted mortality than did either measurement alone.

Thrombocytopenia (platelets <100,000 mm³) is a nonspecific late laboratory finding with low discriminatory performance (AUC: 0.60, sensitivity: 12%) in the context of neonatal sepsis.²² Moreover, platelet counts vary by GA; age-specific thresholds must be used.¹³ Of our population, 37.5% had thrombocytopenia, similar to the reported incidences of

10 to 70%.²³ The initial platelet count did not predict sepsis or mortality; again, thrombocytopenia is a late sign.²² The findings has testified the fact that platelet counts must be used in conjunction with other parameters.^{2,7,22} Logistic regression was employed to define the best combination of predictors. A change in hsCRP ratio >6.08-fold over 24 h and a platelet count <88,000 mm³ on day 0 were associated with a mortality OR of 27.983 (95% CI 9.704-80.697). Other previously investigated variables,^{13,24,25} including the WBC, leukopenia, the NLR, the MPV and the PLR, were either poorly or not at all predictive.

This work has several limitations. A retrospective study design is inevitably associated with a risk of bias. Perinatal outborn data (Apgar scores and birth resuscitation requirements) were recorded by physicians commissioned at other centres and may not be completely accurate. It lacked data on hemodynamic status. The diagnostic utilities of procalcitonin or IL-6 levels were not evaluated; because most local NICUs do not measure these markers in their daily practice of neonatal care. The CBC and hsCRP level are universally accepted sepsis work-up tools. Their combination can alert neonatal care providers to a sepsis risk.

The strength of this work is that it evaluated LOS in a specific group of newborns, lacking intraventricular haemorrhage and surgical intervention; this eliminated false-positive results.

CONCLUSION

Low Apgar scores, NEC and prolonged intubation are independent risk factors for mortality of VLBW infants. Birth in level III and IV NICUs featuring special neonatal care, avoidance of prolonged intubation, and timely prediction of fatal sepsis using changes in the hsCRP ratio and platelet count could prevent LOS mortality in limited-resource settings.

ETHICAL APPROVAL:

The study has been approved by the appropriate ethics committee (Faculty of Medicine, Istinye University, Antalya Medical Park Hospital Ethics Committee, Code: 2019/3; Date: 04.23.2019) and has, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

PATIENTS' CONSENT:

This article does not contain any studies with human participants performed by any of the authors. For this type of study, formal consent is not required.

AUTHORS' CONTRIBUTION:

HO: Designed methods, administration of study for the ethics committee and local authority, participated in data collection, statistical analysis, drafting the article, approval of the final version to be published.

MD: Designed methods, data collection, statistical analysis, drafting the critical revision, approval of the final version to be published.

CONFLICT OF INTEREST:

Authors declare no conflict of interest that may influence either the conduct or the presentation of the research.

REFERENCES

1. Rashwan NI, Hassan MH, Mohey El-Deen ZM, Ahmed AE. Validity of biomarkers in screening for neonatal sepsis - A single center-hospital based study. *Pediatr Neonatol* 2019; **60(2)**:149-55.
2. Beltempo M, Viel-Thériault I, Thibeault R, Julien AS, Piedboeuf B. C-reactive protein for late-onset sepsis diagnosis in very low birth weight infants. *BMC Pediatr* 2018; **18(1)**:16.
3. Adams M, Bassler D. Practice variations and rates of late onset sepsis and necrotizing enterocolitis in very preterm born infants, A review. *Transl Pediatr* 2019; **8(3)**:212-26.
4. Puopolo KM, Benitz WE, Zaoutis TE, Committee on fetus and newborn and committee on infectious diseases. Management of neonates born at ≤ 34 6/7 weeks' gestation with suspected or proven early onset bacterial sepsis. *Pediatrics* 2018; **142**:20182896.
5. Schüller SS, Kramer BW, Villamor E, Spittler A, Berger A, Levy O. Immunomodulation to prevent or treat neonatal sepsis: past, present, and future. *Front Pediatr* 2018; **6**:199.
6. Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. *Lancet* 2017; **390**:1770-80.
7. Hornik CP, Benjamin DK, Becker KC, Benjamin DK, Li J, Clark RH, et al. Use of the complete blood cell count in late-onset neonatal sepsis. *Pediatr Infect Dis J* 2012; **31(8)**:803-7.
8. Hedegaard SS, Wisborg K, Hvas AM. Diagnostic utility of biomarkers for neonatal sepsis-a systematic review. *Infect Dis (Lond)* 2015; **47(3)**:117-24.
9. Rhee C, Kadri SS, Danner RL, Suffredini AF, Massaro AF, Kitch BT, et al. Diagnosing sepsis is subjective and highly variable: A survey of intensivists using case vignettes. *Crit Care* 2016; **20**:89.
10. Leistner R, Thürnagel S, Schwab F, Piening B, Gastmeier P, Geffers C. The impact of staffing on central venous catheter-associated bloodstream infections in preterm neonates-results of nation-wide cohort study in Germany. *Antimicrob Resist Infect Control* 2013; **2(1)**:11
11. Camacho-Gonzalez A, Spearman PW, Stoll BJ. Neonatal infectious diseases: Evaluation of neonatal sepsis. *Pediatr Clin North Am* 2013; **60(2)**:367-89.
12. Polin RA. Committee on Fetus and Newborn. Management of neonates with suspected or proven early-onset bacterial sepsis. *Pediatrics* 2012; **129**:1006-15.
13. Wiedmeier SE, Henry E, Sola-Visner MC, Christensen RD. Platelet reference ranges for neonates, defined using data from over 47,000 patients in a multihospital healthcare system. *J Perinatol* 2009; **29(2)**:130-36.
14. Póvoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, et al. Pilot study evaluating c-reactive protein levels in the assessment of response to treatment of severe bloodstream infection. *Clinical Infectious Diseases*. 2005; **40(12)**:1855-57.
15. Martin A, Faes C, Debevec T, Rytz C, Millet G, Pialoux V. Preterm birth and oxidative stress: Effects of acute physical exercise and hypoxia physiological responses. *Redox Biol* 2018; **17**:315-22.
16. Park JH, Chang YS, Ahn SY, Sung SI, Park WS. Predicting mortality in extremely low birth weight infants: Comparison between gestational age, birth weight, Apgar score, CRIB II score, initial and lowest serum albumin levels. *PLoS One* 2018; **13(2)**:0192232.
17. Shah J, Jefferies AL, Yoon EW, Lee SK, Shah PS. Canadian Neonatal Network. Risk factors and outcomes of late-onset bacterial sepsis in preterm neonates born at < 32 Weeks' gestation. *Am J Perinatol* 2015; **32(7)**:675-82.
18. Lai MY, Tsai MH, Lee CW, Chiang MC, Lien R, Fu RH, et al. Characteristics of neonates with culture-proven bloodstream infection who have low levels of C-reactive protein (≤ 10 mg/L). *BMC Infect Dis* 2015; **15**:320.
19. Escalante MJ, Ceriani-Cernadas JM, D'Apremont I, Bancalari A, Webb V, Genes L, et al. Late onset sepsis in very low birth weight infants in the south american neocosur network. *Pediatr Infect Dis J* 2018; **37(10)**:1022-27.
20. Brasher MI, Patil M, Hagan J, Suresh GK. Mortality and morbidity in outborn extremely low birth weight neonates: A retrospective analysis. *J Perinatol* 2020; **40(2)**:337-43.
21. Hofer N, Zacharias E, Muller W, Resch B. An update on the use of C-reactive protein in early-onset neonatal sepsis: Current insights and new tasks. *Neonatology* 2012; **102(1)**:25-36.
22. Yorulmaz A, Yücel M, Sert S. Diagnostic value of haematological parameters in neonatal sepsis cases. *Ortodogu Med J* 2018; **10**:252-62.
23. Jiang JH, Chiu NC, Huang FY, Kao HA, Hsu CH, Kao H, et al. Neonatal sepsis in the neonatal intensive care unit: characteristics of early versus late onset. *J Microbiol Immunol Infect* 2004; **37(5)**:301-6.
24. Sharma D, Farahbakhsh N, Shastri S, Sharma P. Biomarkers for diagnosis of neonatal sepsis: A literature review. *J Matern Fetal Neonatal Med* 2018; **31(12)**:1646-59.
25. Aydemir C, Aydemir H, Kokturk F, Kulah C, Mungan AG. The cut-off levels of procalcitonin and C-reactive protein and the kinetics of mean platelet volume in preterm neonates with sepsis. *BMC Pediatr* 2018; **18(1)**:253.

